Despite nearly 100% 5-year survival for localised prostate cancer, the survival rate for metastatic prostate cancer significantly declines to 32%. Thus, it is crucial to identify molecular indicators that reflect the progression from localised disease to metastatic prostate cancer.
To search for molecular indicators associated with prostate cancer metastasis, we performed proteomic analysis of rapid autopsy tissue samples from metastatic prostate cancer (N = 8) and localised prostate cancer (N = 2). Then, we utilised multiple independent, publicly available prostate cancer patient datasets to select candidates that also correlate with worse prostate cancer clinical prognosis.
We identified 154 proteins with increased expressions in metastases relative to localised prostate cancer through proteomic analysis. From the subset of these candidates that correlate with prostate cancer recurrence (N = 28) and shorter disease-free survival (N = 37), we identified a 5-gene signature panel with improved performance in predicting worse clinical prognosis relative to individual candidates.
Our study presents a new 5-gene signature panel that is associated with worse clinical prognosis and is elevated in prostate cancer metastasis on both protein and mRNA levels. Our 5-gene signature panel represents a potential modality for the prediction of prostate cancer progression towards the onset of metastasis.
British journal of cancer. 2024 Oct 14 [Epub ahead of print]
Michelle Shen, Fernando García-Marqués, Arvind Muruganantham, Shiqin Liu, James Robert White, Abel Bermudez, Meghan A Rice, Kelsey Thompson, Chun-Liang Chen, Chia-Nung Hung, Zhao Zhang, Tim H Huang, Michael A Liss, Kenneth J Pienta, Sharon J Pitteri, Tanya Stoyanova
Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA, USA., Department of Radiology, Stanford University, Stanford, CA, USA., Resphera Biosciences LLC, Baltimore, MD, USA., Department of Molecular Medicine, UT Health San Antonio, San Antonio, TX, USA., Department of Urology, UT Health San Antonio, San Antonio, TX, USA., Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, MD, USA., Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA, USA. .